MedTrace Logo

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

NCT00930943 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-05-09

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether extended-release oxymorphone hydrochloride taken orally with a high-fat meal, generating an approximately 50% higher Cmax, impacts cognitive functioning, using Cambridge Neuropsychological Test Automated Battery (CANTAB) tests, to a greater extent than when taking under conditions of fasting.

Conditions

Interventions

DRUG

Oxymorphone ER

40 mg qd twice

Sponsors & Collaborators

  • MedVadis Research Corporation

    lead INDUSTRY

Principal Investigators

  • Egilius LH Spierings, MD, PhD · MedVadis Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930943 on ClinicalTrials.gov